This study not only provides a theoretical foundation for considering STA as a targeted therapeutic agent for HCC but also highlights the potential application value of STAT3 and FN1 in HCC treatment, offering new insights and directions for targeted therapy research in this context. The gene discussed is STAT3; the disease is hepatocellular carcinoma.